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Abstract
Background: Lyme Neuroborreliosis (LNB) in a human immunodeficiency virus (HIV) positive patient is a rare
co-infection and has only been reported four times in literature. No case of an HIV patient with a
meningoencephalitis due to LNB in combination with HIV has been described to date.
Case presentation: A 51 year old woman previously diagnosed with HIV presented with an atypical and severe
LNB. Diagnosis was made evident by several microbiological techniques. Biochemical and microbiological recovery
during treatment was rapid, however after treatment the patient suffered from severe and persistent sequelae.
Conclusions: A clinician should consider LNB when being confronted with an HIV patient with focal encephalitis,
without any history of Lyme disease or tick bites, in an endemic area. Rapid diagnosis and treatment is necessary
in order to minimize severe sequelae.
Background
Lyme Neuroborreliosis (LNB) in a human immunodefi-
ciency virus (HIV) positive patient is a rare co-infection
and has only been reported four times [1-4]. All pub-
lished cases are early presentations of Lyme disease and
no report of a meningoencephalitis due to B. burgdorferi
in an HIV patient has been made to date. We present a
case of an HIV positive patient that presented with a
severe LNB, without any previous sign of Lyme disease.
Case presentation
A 51-year-old woman, diagnosed with HIV 10 years
before, presented early spring 2006 at the outpatient
clinic in the west of the Netherlands. She had noticed
an altered gait that was progressive since three months.
Strength and sensibility were unaltered, but there was
paresthesia in both legs. She also had problems unbut-
toning clothing with both hands. There was no com-
plaint of headache, photophobia or visual changes. The
medical history showed an anxiety disorder, hyperten-
sion and glaucoma. At presentation, the patient had
been using HAART for six years (zidovudine, lamivu-
dine and nevirapine) in combination with antihyperten-
sive medication and a selective serotonin reuptake
inhibitor. There was no indication for antibiotic prophy-
laxis. She had no history of tick bites, rash, erythema
migrans or other signs of early or late-stage Lyme borre-
liosis. However, she frequently worked in her garden in
an area where B. burgdorferi is endemic. Neurological
examination revealed a bipyramidal walking pattern, an
intention tremor of the posture and the hands, bilateral
hyperreflexia in her legs and arms, a positive Hoffman-
Trömner and a bilateral Babinski. There were no menin-
geal signs and all cranial nerve function was intact. RR
was 190/113 and temperature was normal. Routine
laboratory tests showed no signs of infection; blood leu-
cocytes level was 5,9*10
9/l. Plasma HIV RNA load was
undetectable, CD4+ T lymphocyte count was 501/μl.
A lumbar puncture was performed; the opening pres-
sure was 28 cm H2O. The cerebrospinal fluid (CSF)
showed a leucocytosis of 201/μl, 70% T-lymphocytes, 6%
NK-cells, and 6% B-lymphocytes, glucose 2 mmol/l
(serum glucose 6,2 mmol/l), protein 1,26 g/L. By isoelec-
tric focussing oligoclonal IgG was detected intrathecally,
but there was no evidence of a monoclonal B-cell popu-
lation. Cytology and immunophenotyping of the
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malignancies.
A nM R Io ft h es p i n ea sw e l la sb r a i nw a sp e r f o r m e d .
No abnormalities were detected in the spine, but in the
midline of the pontine region a hyperintense signal was
seen on DUAL and FLAIR view (Figure 1-2). This lesion
did not enhance under gadolinium.
CSF was examined and found PCR negative for HIV
RNA, neurotropic viruses (Cytomegalovirus, Epstein
Barr, Varicella zoster virus, Herpes simplex virus, JC
virus), tuberculosis, toxoplasmosis, Bartonella and Tre-
ponema pallidum. CSF and serum serology was negative
for T. pallidum and cryptococcal antigens. Serology for
Bartonella, Babesia, Anaplasma and Ehrlichia showed no
indication of an active infection. Culture was negative
for cryptococcosis, tuberculosis and other common
bacteria. Results for Lyme disease showed specific
intrathecal IgG antibodies against B. burgdorferi in
ELISA, no additional bands on blot were seen in CSF
compared to serum. The intrathecal antibody index (AI)
was positive (AI 19; cut off 0.3), indicating a specific
production of antibodies to Borrelia in the CSF (IDEIA,
Oxiod, UK). Also real-time PCR for Borrelia burgdorferi
OspA conducted on the CSF was positive [5]. Serum
antibodies against Borrelia were detected with the
QuickELISA Borrelia C6 assay (Lyme index >10)
(Immunetics, Boston, USA), and their presence was con-
firmed by a positive band for p100/83, VlsE, p41(i), p39
and DbpA on the RecomBlot Borrelia IgG assay (Mikro-
gen, Martinsreid, Germany). A serum from three years
preceding this clinical presentation tested completely
negative for antibodies against B. burgdorferi.
T h ed i a g n o s i so faL y m em e n i n g o e n c e p h a l i t i sw a s
made. The patient was treated intravenously with cef-
triaxone 2 g/day for 1 month according to the EUCALB
guideline. During the first week of treatment her clinical
condition worsened. She was no longer able to walk
independently and was forced to use a wheelchair. The
cerebral MRI however showed decline of the hyperin-
tense region at the end of intravenous treatment. An
MRI performed one month later showed no abnormal-
ities at all (Figure 3). In addition, posttreatment CSF
showed a reduction in pleocytosis (7/μl), an absence of
intrathecal specific antibodies against Borrelia and the
real-time PCR for OspA on the CSF was negative. After
a year of regular check up the patients’ physical exami-
nation showed paraparesis of the right m. iliopsoas
grade 4, right hamstrings grade 3, right footlifters
degree 4 and hyperreflexia of both legs with Babinski
signs. The bipyramidal walking pattern was still present.
The patient was able to stand alone and walk with a
Figure 1 DUAL TSE at presentation with a diffuse lesion
located centrally in the pons.
Figure 2 FLAIR at presentation with a diffuse lesion located
centrally in the pons.
Figure 3 FLAIR seven months after treatment, the lesion
completely resolved.
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regular check up for four years.
Discussion
We describe a case of a patient with an HIV infection
and severe neurology and MRI lesions due to a B. burg-
dorferi central nervous system (CNS) infection. After
treatment with ceftriaxone the laboratory parameters of
infection disappeared along with the abnormalities on
MRI, however the patient persistently suffered from
severe verifiable sequelae.
Diagnosing Lyme disease using serology in patients
with HIV is complicated due to reduced positive predic-
tive value of serology in HIV patients [6]. Also, false
positive serologic findings are described in patients with
neurological infections with other spirochetes such as
Treponema pallidum [7]. Present patients’ clinical pre-
sentation was compatible with a localised cerebral infec-
tion with B. burgdorferi, confirmed by the positive
serology, intrathecal specific anti-Borrelia antibody pro-
duction and a positive real-time PCR for B. burgdorferi
OspA on the CSF. The sensitivity of the OspA real-time
PCR on CSF is only about 50% but the specificity is
very high >99% [5]. In HIV positive patients where diag-
nosis of LNB by an indirect method such as serology is
already compromised, a method where the microorgan-
ism is detected directly is of great value.
Little is known about the course of LNB in HIV
patients. Animal models have shown that CD4 + T-cells
facilitate clearance of B. burgdorferi [8]. In recent studies
the importance of CXCL13 in B-cell recruitment in
patients with LNB has been suggested [9]. In HIV infec-
tion the levels of CXCL13 in serum are elevated and the
receptor CXCR5 on B-cells is down regulated causing
impaired trafficking of B-cells [10]. Inadequate humoral
response could lead to accelerated progression of LNB.
In animal experiments immunodeficiency leads to higher
spirochete burdens and higher infectivity of B. burgdor-
feri [11]. In contrast, reports from a study where Lyme
borreliosis patients were treated with immunosuppressive
agents, no significant effect on clinical course and
response to treatment was observed [12]. T. pallidum is a
spirochete and more is known about disease course in
syphilis HIV co-infection. Disease course is altered in
T. pallidum and HIV co-infections; there is a higher
rate of asymptomatic infection, a faster progression to
secondary disease which is often more aggressive with a
significant predisposition for the development of neuro-
logical complaints. However, after treatment HIV positive
patients recover as well as the HIV negative population
[13,14]. In co-infections of HIV and Leptospira species. a
more fulminant disease course has also been suggested
[15]. For LB and HIV co-infections no such synergistic
complications have been described in patients to date.
Despite the high incidence of HIV, co-infection with
B. burgdorferi is not reported very often [1-4]. The low
incidence of HIV LNB co-infections can not be easily
explained. In HIV infection antibiotic prophylaxis is
sometimes prescribed but none of the reported cases of
HIV patients with LNB used antibiotic prophylaxis. Pro-
phylaxis usually consists of cotrimoxazole, which is inef-
fective against B. burgdorferi which renders a positive
effect of antibiotic prophylaxis on the development of
Lyme disease unlikely [16]. There is no data about anti-
borrelia activity for anti-retroviral mediaction but an
association seems unlikely because three of the five
described patients were using anti-retroviral medication.
All reported LNB HIV patients’ results have been sum-
marized in table 1 and table 2. Case 1 had had an EM
and presented with a rather classical course of a bilateral
facial palsy shortly after noticing the EM, rapidly
improving on IV ceftriaxone treatment. HIV serology
was found positive during workup for the cause of his
bilateral facial palsy, CD4+ count was decreased at that
time. Case 2 had a low CD4+ count with progression to
neuroborreliosis, despite treatment for his recent early
LB. Serology in CSF and serum was clearly positive for
an early LNB. After IV treatment with ceftriaxone he
recovered completely. Case 3 had a very low CD4+
count and was the only case that met the criteria for
AIDS. He primarily showed a slow seroconversion
although this was only determined by indirect immuno-
fluorescence and not by ELISA or Western Blot. Four
months after presentation with a painful radiculitis he
had low detectable Ig titers against Borrelia by ELISA
and Western Blot. He recovered completely. Case 4 had
a moderately low CD4+ count and had a classical course
of EM, followed by malaise and a facial palsy with signs
of early LNB in serology of CSF and serum. He
responded well to treatment with IV cefotaxime. Case 5
the present case had a moderately low CD4+ T-lympho-
cyte count and had rapid progression to a meningoence-
phalitis. This is the only case described to date of an
HIV patient with a Lyme meningoencephalitis. The
course of disease was rapid and atypical with a primary
presentation of altered gait due to Lyme meningoence-
phalitis, which is an uncommon presentation of neuro-
borreliosis, found in only 3-5% of patients with LNB
[17]. Diagnosis was made obvious due to positive PCR
combined with positive IgG serology in CSF and serum.
After treatment microbiological response was rapid. AI
returned negative after two months, which is a rapid
decline but not uncommon in literature [18]. Despite
this rapid improvement biochemically and microbiologi-
cally severe sequelae remained. Posttreatment sequelae
are rare. Patients with posttreatment sequelae have com-
plaints of fatigue, cognitive impairment and paresthesia
but sequelae are rarely as severe after a relatively short
van Burgel et al. BMC Neurology 2010, 10:117
http://www.biomedcentral.com/1471-2377/10/117
Page 3 of 5duration of illness as in this case [17,19,20]. Although
this patient had complaints for only three months, it is
likely that earlier recognition and treatment of LNB in
this patient would have led to less neurological damage
and therefore to better recovery.
Conclusions
A clinician should consider LNB as a rare possible cause
of focal encephalomyelitis in an HIV patient, without
any history of Lyme disease or tick bites in an area
endemic for Lyme disease. Diagnosis of LNB can be
compromised in HIV co-infected patients, however
when applying optimal serological and molecular diag-
nostic techniques confirming LNB is imminent. This
report raises the possibility that LNB might take a more
severe course in immunocompromised patients, such as
those with HIV infection.
Consent
Written informed consent was obtained from the
patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
Table 2 Laboratory data from all patients with LNB and HIV reported in literature.
Case no.* Age Sex Yrs HIV Blood CD4+
count (/μl)*
CSF cell count (/μl) Protein (g/l) CT/MRI Serum Serology CSF Serology
1 39 M 0 386 30 1,02 nd IgG + IgG +
ELISA/WB ELISA/WB
2 39 M 1 250 496 3,62 nd IgM +/IgG - IgG +
3 50 M 10 70 ‘aseptic meningitis’ nd ELISA IgG + (month 4) ELISA IgG + (month 4)
WB IgG + WB IgG +
IF Negative >4 months
4 46 M 16 426 416 3,02 normal IgM +/IgG + IgM +/IgG +
ELISA/WB ELISA/WB
5 51 F 11 501 200 1,26 abnormal IgM -/IgG + IgM -/IgG +
ELISA/WB ELISA/WB
*Case 1[1], 2[2], 3[3], 4[4], 5 this report. Serology was performed by ELISA, Western blot (WB), or indirect immunofluorescence (IF). (nd = not done)* normal range
peripheral blood; case 1: 580-1570/μl, case 3: 600-1000/μl, case 5: 560-1490/μl
Table 1 Clinical data from all patients with LNB and HIV reported in literature.
Case
no.*
Anti-
retroviral
Antibiotic
prophylaxis
Skin
manifestations
Presentation Treatment Clinical recovery
1 none none Annular
erythematous
lesion
Several weeks later: fever,
bilateral facial palsy
IV ceftriaxone
2 g/day 14 days
After treatment vast improvement
2 months, complete recovery
2 Zidovudine none reported Erythema Headache, painful limbs,
weight loss, pneumonia
Primairily: PO
Azithromycin
Progression to neuroborreliosis
Saquinavir 1 day 500 mg,
4 days 250 mg
Zalcitabine 2 weeks later: fever, diplopia IV ceftriaxone
2 g/day 14 days
Improved rapidly
3 Zidovudine none reported Erythematous
lesion
4 weeks later:: radiculitis IV ceftriaxone
2 g/day 15 days
Complete recovery
Didanosine 18 months, no relapse
4 none none reported Multiple Fever, chills, arthralgias IV ceftotaxime
2 g TID 21 days
After treatment mild facial palsy
Maculous
erythemas
2 weeks later left facial palsy 6 months, slight hypokinesia face
5 Zidovudine none None Altered gait for months IV ceftriaxone
2 g/day 1 month
After treatment severe sequelae
Lamivudine 3 years, no relapse
Nevirapine
*Case 1[1], 2[2], 3[3], 4[4], 5 this report.
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